BC Week In Review | Oct 12, 2015
Clinical News

Gerilimzumab: Phase I started

RuiYi began a double-blind, placebo-controlled Phase I trial to evaluate single and multiple ascending doses of gerilimzumab in healthy volunteers. RuiYi has rights to develop and commercialize gerilimzumab from arGEN-X under a 2012 deal. arGEN-X...
BC Innovations | Dec 4, 2014
Cover Story

GPCRs' grand plans

In a move to expand tenfold the number of known 3D structures of the highly druggable class of GPCRs, Amgen Inc. , Ono Pharmaceutical Co. Ltd. and Sanofi have teamed up with three academic organizations to...
BC Week In Review | Sep 8, 2014
Company News

RuiYi management update

RuiYi Inc. , La Jolla, Calif.   Business: Autoimmune, Cancer   Hired: Mark Saad as CFO, formerly CFO of Cytori Therapeutics Inc.  ...
BC Innovations | Jul 31, 2014
Translation in Brief

Translational tidbits

Benjamin Boettner, Associate Editor, and Chris Cain, Michael J. Haas and Kai-Jye Lou, Senior Writers  Quantitative boost for CSHL The Simons Foundation has donated $50 million to Cold Spring Harbor Laboratory to establish the Simons...
BC Week In Review | Jun 16, 2014
Financial News

RuiYi completes venture financing

RuiYi Inc. , La Jolla, Calif.   Business: Autoimmune, Cancer   Date completed: 6/11/14   Type: Venture financing   Raised: $4 million   Investor: Silicon Valley Bank   Note: The offering is debt.  ...
BC Week In Review | Jun 16, 2014
Company News

RuiYi, ShanghaiTech University deal

RuiYi partnered with the university's iHuman Institute to apply RuiYi's intermembranous conformation antigen presenting system (iCAPS) to create mAbs with specific binding to GPCRs. The iCAPS technology can isolate and present functional GPCRs in their...
BC Week In Review | Mar 31, 2014
Financial News

RuiYi completes venture financing

RuiYi Inc. , La Jolla, Calif.   Business: Autoimmune, Cancer   Date completed: 3/27/14   Type: Venture financing   Raised: $15 million   Investors: 5AM Ventures; Versant Ventures; Apposite Capital; SR One; MS Ventures; Aravis Venture...
BC Extra | Mar 28, 2014
Financial News

RuiYi raises $15 million in B round

RuiYi Inc. (La Jolla, Calif.) raised $15 million in a series B round from existing investors 5AM Ventures; Versant Ventures; Apposite Capital; SR One; MS Ventures; and Aravis Venture. RuiYi also hired Erik Karrer as...
BC Week In Review | May 20, 2013
Company News

Genor Biopharma, RuiYi deal

RuiYi granted Genor exclusive rights to develop and commercialize RYI-008 ( ARGX-109 ) in China. RYI-008, an anti-IL-6 mAb, is in preclinical development for cancer and autoimmune indications. RuiYi said the product will first be developed for...
BioCentury | May 20, 2013
Finance

Merck Serono's earnest money

Four years after launching a strategic venture fund, the Merck Serono S.A. unit of Merck KGaA is making a long-term commitment with an infusion of €60 million ($77.8 million). While the fund's focus will remain...
Items per page:
1 - 10 of 26
BC Week In Review | Oct 12, 2015
Clinical News

Gerilimzumab: Phase I started

RuiYi began a double-blind, placebo-controlled Phase I trial to evaluate single and multiple ascending doses of gerilimzumab in healthy volunteers. RuiYi has rights to develop and commercialize gerilimzumab from arGEN-X under a 2012 deal. arGEN-X...
BC Innovations | Dec 4, 2014
Cover Story

GPCRs' grand plans

In a move to expand tenfold the number of known 3D structures of the highly druggable class of GPCRs, Amgen Inc. , Ono Pharmaceutical Co. Ltd. and Sanofi have teamed up with three academic organizations to...
BC Week In Review | Sep 8, 2014
Company News

RuiYi management update

RuiYi Inc. , La Jolla, Calif.   Business: Autoimmune, Cancer   Hired: Mark Saad as CFO, formerly CFO of Cytori Therapeutics Inc.  ...
BC Innovations | Jul 31, 2014
Translation in Brief

Translational tidbits

Benjamin Boettner, Associate Editor, and Chris Cain, Michael J. Haas and Kai-Jye Lou, Senior Writers  Quantitative boost for CSHL The Simons Foundation has donated $50 million to Cold Spring Harbor Laboratory to establish the Simons...
BC Week In Review | Jun 16, 2014
Financial News

RuiYi completes venture financing

RuiYi Inc. , La Jolla, Calif.   Business: Autoimmune, Cancer   Date completed: 6/11/14   Type: Venture financing   Raised: $4 million   Investor: Silicon Valley Bank   Note: The offering is debt.  ...
BC Week In Review | Jun 16, 2014
Company News

RuiYi, ShanghaiTech University deal

RuiYi partnered with the university's iHuman Institute to apply RuiYi's intermembranous conformation antigen presenting system (iCAPS) to create mAbs with specific binding to GPCRs. The iCAPS technology can isolate and present functional GPCRs in their...
BC Week In Review | Mar 31, 2014
Financial News

RuiYi completes venture financing

RuiYi Inc. , La Jolla, Calif.   Business: Autoimmune, Cancer   Date completed: 3/27/14   Type: Venture financing   Raised: $15 million   Investors: 5AM Ventures; Versant Ventures; Apposite Capital; SR One; MS Ventures; Aravis Venture...
BC Extra | Mar 28, 2014
Financial News

RuiYi raises $15 million in B round

RuiYi Inc. (La Jolla, Calif.) raised $15 million in a series B round from existing investors 5AM Ventures; Versant Ventures; Apposite Capital; SR One; MS Ventures; and Aravis Venture. RuiYi also hired Erik Karrer as...
BC Week In Review | May 20, 2013
Company News

Genor Biopharma, RuiYi deal

RuiYi granted Genor exclusive rights to develop and commercialize RYI-008 ( ARGX-109 ) in China. RYI-008, an anti-IL-6 mAb, is in preclinical development for cancer and autoimmune indications. RuiYi said the product will first be developed for...
BioCentury | May 20, 2013
Finance

Merck Serono's earnest money

Four years after launching a strategic venture fund, the Merck Serono S.A. unit of Merck KGaA is making a long-term commitment with an infusion of €60 million ($77.8 million). While the fund's focus will remain...
Items per page:
1 - 10 of 26